What do systematic reviews say?

Nebulized budesonide vs viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nebulized budesonide vs viscous budesonide

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Budesonide 15 mg vs placebo

Budesonide 15 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 2.25 [1.35, 3.76]
  2 studies · 181 participants
  Moderate

Budesonide 15 mg vs placebo

Budesonide 15 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐… compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 2.34 [0.83, 6.63]
  1 study · 51 participants
  Low

Budesonide 15 mg vs placebo

Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.55 [0.45, 5.34]
  2 studies · 181 participants
  Low

Budesonide 15 mg vs placebo

Budesonide 15 mg probably leads to lower withdrawal due to disease worsening compared with placebo (moderate certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.57 [0.36, 0.89]
  2 studies · 181 participants
  Moderate

Budesonide 15 mg vs placebo

Budesonide 15 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.4 [0.84, 2.34]
  2 studies · 181 participants
  Moderate

Budesonide 6‐9 mg vs azathioprine (AZA)

It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).

• Budesonide for maintenance of remission in Crohn's disease 2014 · Cochrane Headline outcomes only
  RR 0.81 [0.61, 1.08]
  1 study · 77 participants
  Very low

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 2.25 [1.5, 3.39]
  3 studies · 900 participants
  Moderate

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.73, 1.27]
  2 studies · 440 participants
  Moderate

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.23 [0.63, 2.4]
  2 studies · 440 participants
  Low

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.63 [0.21, 1.91]
  2 studies · 512 participants
  Low

Budesonide MMX® 6 mg vs placebo

It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.13 [0.97, 1.32]
  2 studies · 512 participants
  Very low

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.1 [0.55, 2.22]
  2 studies · 512 participants
  Low

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.3 [0.99, 1.7]
  2 studies · 442 participants
  Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in remission (combined clinical and endoscopic remission) compared with entocort EC 9mg (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.38 [0.72, 2.65]
  1 study · 212 participants
  Low

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg probably leads to higher endoscopic improvement compared with placebo (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.29 [1.01, 1.66]
  2 studies · 442 participants
  Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with entocort EC 9mg (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.28 [0.9, 1.82]
  1 study · 212 participants
  Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in endoscopic improvement compared with entocort EC 9mg (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.14 [0.82, 1.6]
  1 study · 212 participants
  Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in histologic remission compared with entocort EC 9mg (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.21 [0.64, 2.31]
  1 study · 212 participants
  Low